留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌早期诊断中的生物标志物

刘熙称 王艺颖 童曼曼 秦俊杰

刘熙称, 王艺颖, 童曼曼, 等. 肝细胞癌早期诊断中的生物标志物[J]. 临床肝胆病杂志, 2021, 37(1): 176-179. DOI: 10.3969/j.issn.1001-5256.2021.01.038
引用本文: 刘熙称, 王艺颖, 童曼曼, 等. 肝细胞癌早期诊断中的生物标志物[J]. 临床肝胆病杂志, 2021, 37(1): 176-179. DOI: 10.3969/j.issn.1001-5256.2021.01.038
LIU XC, WANG YY, TONG MM, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(1): 176-179. DOI: 10.3969/j.issn.1001-5256.2021.01.038
Citation: LIU XC, WANG YY, TONG MM, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma [J]. J Clin Hepatol, 2021, 37(1): 176-179. DOI: 10.3969/j.issn.1001-5256.2021.01.038

肝细胞癌早期诊断中的生物标志物

DOI: 10.3969/j.issn.1001-5256.2021.01.038
详细信息
    作者简介:

    刘熙称(1995—),男,主要从事肝病的治疗

    通讯作者:

    秦俊杰,qinjj.1982@163.com

  • 作者贡献声明:刘熙称负责课题设计,撰写论文;刘熙称、王艺颖、童曼曼参与文献搜集,修改论文;秦俊杰负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R735.7

Biomarkers for the early diagnosis of hepatocellular carcinoma

  • 摘要: 晚期肝细胞癌(HCC)患者预后通常较差,如若能早期诊断,并采取行之有效的治疗措施则可显著提高患者生存率。目前,AFP是检测HCC应用最广泛的血清标志物。然而,在一些HCC患者中并未发现AFP的升高。分析了AFP、乙型肝炎核心相关抗原、液体活检技术、微小RNA、长链非编码RNA及外泌体在HCC早期诊断中的应用潜力,通过探讨其研究进展,为HCC早期诊断方法的探索提供依据。
  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
    [2] LI C, XU X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma[J]. Cell Mol Life Sci, 2019, 76(21): 4203-4219. DOI: 10.1007/s00018-019-03215-0
    [3] TZARTZEVA K, OBI J, RICH NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A Meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718. DOI: 10.1053/j.gastro.2018.01.064
    [4] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
    [5] PAN JH, ZHOU H, ZHAO XX, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review)[J]. Int J Mol Med, 2018, 41(4): 1809-1816. http://europepmc.org/articles/PMC5810235/
    [6] LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP Negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2): 599-603. DOI: 10.1007/s12253-019-00585-5
    [7] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK202002001.htm
    [8] GRANDHI MS, KIM AK, RONNEKLEIV-KELLY SM, et al. Hepatocellular carcinoma: From diagnosis to treatment[J]. Surg Oncol, 2016, 25(2): 74-85. DOI: 10.1016/j.suronc.2016.03.002
    [9] CHEN S, CHEN H, GAO S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(4): 312-320. DOI: 10.1111/hepr.12739
    [10] BRUIX J, SHERMAN M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199
    [11] TSUCHIYA N, SAWADA Y, ENDO I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(37): 10573-10583. DOI: 10.3748/wjg.v21.i37.10573
    [12] CHOI J, KIM GA, HAN S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J]. Hepatology, 2019, 69(5): 1983-1994. DOI: 10.1002/hep.30233
    [13] DING Y, LIU K, XU Y, et al. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma[J]. Cancer Med, 2020, 9(9): 3057-3069. DOI: 10.1002/cam4.2968
    [14] MAK LY, WONG DK, CHEUNG KS, et al. Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther, 2018, 47(1): 43-54. DOI: 10.1111/apt.14376
    [15] TADA T, KUMADA T, TOYODA H, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics[J]. J Hepatol, 2016, 65(1): 48-56. DOI: 10.1016/j.jhep.2016.03.013
    [16] TSENG TC, LIU CJ, HSU CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load[J]. Gastroenterology, 2019, 157(6): 1518-1529.e3. DOI: 10.1053/j.gastro.2019.08.028
    [17] SUZUKI Y, MAEKAWA S, KOMATSU N, et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma[J]. Hepatol Res, 2019, 49(1): 51-63. DOI: 10.1111/hepr.13277
    [18] YE Q, LING S, ZHENG S, et al. Liquid biopsy in hepatocellular carcinoma: Circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114. DOI: 10.1186/s12943-019-1043-x
    [19] BANINI BA, SANYAL AJ. The use of cell free DNA in the diagnosis of HCC[J]. Hepatoma Res, 2019, 5: 34. http://www.researchgate.net/publication/341001255_The_use_of_cell_free_DNA_in_the_diagnosis_of_HCC
    [20] XU RH, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997
    [21] CHENG Y, LUO L, ZHANG J, et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma[J]. J Gastrointest Surg, 2019, 23(12): 2354-2361. DOI: 10.1007/s11605-018-04067-y
    [22] LI Y, ZHAO J, YU S, et al. Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis[J]. Clin Chem, 2019, 65(6): 798-808. DOI: 10.1373/clinchem.2018.301291
    [23] CHEN R, XU X, TAO Y, et al. Exosomes in hepatocellular carcinoma: A new horizon[J]. Cell Commun Signal, 2019, 17(1): 1. DOI: 10.1186/s12964-018-0315-1
    [24] LI LM, LIU ZX, CHENG QY. Exosome plays an important role in the development of hepatocellular carcinoma[J]. Pathol Res Pract, 2019, 215(8): 152468. DOI: 10.1016/j.prp.2019.152468
    [25] WANG XQ, LU QF. Research progress of exocrine miRNAs of hepatic carcinoma[J]. Int J Lab Med, 2019, 40(10): 1248-1251. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201910023.htm

    王秀芹, 路其凤. 肝癌外泌体miRNAs研究进展[J]. 国际检验医学杂志, 2019, 40(10): 1248-1251. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSQ201910023.htm
    [26] XU H, CHEN Y, DONG X, et al. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(6): 710-716. DOI: 10.1158/1055-9965.EPI-17-0770
    [27] XU H, DONG X, CHEN Y, et al. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma[J]. Clin Chem Lab Med, 2018, 56(3): 479-484. DOI: 10.1515/cclm-2017-0327
    [28] SARTORIUS K, SARTORIUS B, WINKLER C, et al. The biological and diagnostic role of miRNA's in hepatocellular carcinoma[J]. Front Biosci (Landmark Ed), 2018, 23: 1701-1720. DOI: 10.2741/4668
    [29] ZHANG YC, XU Z, ZHANG TF, et al. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(34): 9853-9862. DOI: 10.3748/wjg.v21.i34.9853
    [30] ZIOGAS IA, SIOUTAS G, MYLONAS KS, et al. Role of MicroRNA in the diagnosis and management of hepatocellular carcinoma[J]. Microrna, 2020, 9(1): 25-40.
    [31] ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697
    [32] JIN Y, WONG YS, GOH BKP, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 10464. DOI: 10.1038/s41598-019-46872-8
    [33] AN Y, GAO S, ZHAO WC, et al. Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(24): 2596-2604. DOI: 10.3748/wjg.v24.i24.2596
    [34] KLEC C, GUTSCHNER T, PANZITT K, et al. Involvement of long non-coding RNA HULC (highly up-regulated in liver cancer) in pathogenesis and implications for therapeutic intervention[J]. Expert Opin Ther Targets, 2019, 23(3): 177-186. DOI: 10.1080/14728222.2019.1570499
    [35] HUANG Q, SHA H, CHEN L, et al. Expression levels of plasma lncRNA MALAT1, LincRNA-p21 and GAS5 in patients with multiplemyeloma and chroniclymphocytic leukemia and their diagnostic significances[J]. J Jilin Univ(Med Edit), 2018, 44(2): 339-345. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201802024.htm

    黄琦, 沙辉, 陈龙, 等. 多发性骨髓瘤和慢性淋巴细胞白血病患者血浆lncRNA MALAT1、LincRNA-p21和GAS5的表达水平及其诊断意义[J]. 吉林大学学报(医学版), 2018, 44(2): 339-345. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201802024.htm
    [36] ZHANG LH, DONG XJ, WANG HB, et al. Research advance of long non-coding RNA in diagnosis and prognosis of hepatocellular carcinoma[J/CD]. Chin J Clin Lab Manage(Electronic Edition), 2019, 7(3): 129-132. (in Chinese)

    张丽红, 董学君, 王宏斌, 等. 长链非编码RNA在肝细胞癌诊断及预后中的研究进展[J/CD]. 中华临床实验室管理电子杂志, 2019, 7(3): 129-132.
    [37] ZENG YL, GUO ZY, SU HZ, et al. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(48): 6902-6915. http://www.ncbi.nlm.nih.gov/pubmed/31908394
    [38] QI J, LI J, SUN J, et al. Long Non-Coding RNA IGF2AS in serum may be a biomarker for diagnosis of hepatitis B virus-related hepatocellular carcinoma[J]. Clin Lab, 2019, 65(12): 2349-2354. http://www.ncbi.nlm.nih.gov/pubmed/31850718
    [39] LI SL, TAO Y. Diagnostic value of long-chain non-coding RNA HOTAIR, H19, HULC combined for HBV-related liver cancer[J]. Pract J Cancer, 2020, 35(2): 219-222. (in Chinese)
  • 加载中
计量
  • 文章访问数:  108
  • HTML全文浏览量:  23
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-05-19
  • 修回日期:  2020-06-09
  • 刊出日期:  2021-01-18
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回